Search Results for "Zalicus Research"
Original Source: Zalicus Inc
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo⢠(hydromorphone HCl) extended-release tablets (marketed by Covidien), for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and our Ion channel program, which is advancing a lead candidate into clinical development fo...
Matching Channels
None
Matching News
By Jorge Aura:Zalicus Inc (ZLCS) is a biopharmaceutical company that has reached agreements with important companies such as Novartis (NVS), Covidien (COV), Sanofi (SNY) and Amgen (AMGN) among others....
Reconsidering Zalicus And Antares In Light Of Shakeups
By James Stocklasar Thomas Jr.:Lesson learned. Or should I write, Again and again? Just when you give your heart and soul to a biotech company, you discover just how risky they can be. Such is Tuesd...
Is Zalicus Really A Bad Investment?
ByHarriet Stockpotter: I confess that I bought Zalicus' (ZLCS) shares after reading information poured in several articles, and I do not regret buying them. However, it is also true that the company g...
Zalicus CEO Disposes Of 844,090 Shares
By James Stocklasar Thomas Jr.:In after-hours, a change in beneficial ownership in Zalicus (ZLCS) showed up on the radar screen. But investors will be surprised to read that the name is CEO Mark Corri...
Zalicus drops Synavive RA drug after disappointing Ph IIb results
US biotech firm Zalicus (Nasdaq: ZLCS) saw its shares plunge nearly 40% to $0.84 in afternoon trading Monday, after saying it would discontinue further development of its rheumatoid arthritis (RA) dru...
Zalicus to Present at the 2013 BIO CEO & Investor Conference
Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus managem...
Zalicus to Present at the 2012 JMP Securities Healthcare Conference
Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today anno...
Zalicus shifts focus to pain after lead project Synavive fails in arthritis
It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive,...
Matching PubMed Articles
Complicity in stem cell research: the case of induced pluripotent stem cells.
Many who object to human embryonic stem cell (hESC) research because they believe it involves complicity in embryo destruction have welcomed induced pluripotent stem cell (iPSC) research as an ethical...
Withdrawing from Research: A Rethink in the Context of Research Biobanks.
It is generally assumed in research ethics that research participants have an unconditional right to withdraw from research without any detriment or reprisal. This paper analyses this right in the con...
Stitching Together Cross-border Research.
European research has been hampered by fragmented national research programs. Is joint programming the answer? Colin Macilwain investigates.
Is the use of sentient animals in basic research justifiable?
ABSTRACT: Animals can be used in many ways in science and scientific research. Given that society values sentient animals and that basic research is not goal oriented, the question is raised: "Is the...
